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Andrew Ruszkiewicz2,5,8, Jim Manavis6 and Michael P Brown1,2,7,8,10Abstract
Background: The lupus-associated (La)-specific murine monoclonal antibody DAB4 (APOMAB®) specifically binds
dead cancer cells. Using DAB4, we examined La expression in human lung cancer samples to assess its suitability as
a cancer-selective therapeutic target. We evaluated the safety and effectiveness of radioimmunotherapy (RIT) using
DAB4 radiolabeled with Lutetium-177 (177Lu) in the murine Lewis Lung (LL2) carcinoma model, and determined
whether combining RIT with DNA-damaging cisplatin-based chemotherapy, a PARP inhibitor (PARPi), or both alters
treatment responses.
Methods: The expression of La mRNA in human lung cancer samples was analysed using the online database
Oncomine, and the protein expression of La was examined using a TissueFocus Cancer Survey Tissue Microarray.
The binding of DAB4 to cisplatin-treated LL2 cells was assessed in vitro. LL2 tumour-bearing mice were administered
escalating doses of 177Lu-DAB4 alone or in combination with chemotherapy, and tumour growth and survival
measured. Biodistribution analysis was used to determine tissue uptake of 177Lu-DAB4 or its isotype control
(177Lu-Sal5), when delivered alone or after chemotherapy. PARPi (rucaparib; AG-014699) was combined with
chemotherapy and the effects of combined treatment on tumour growth, tumour cell DNA damage and death,
and intratumoural DAB4 binding were also analysed. The effect of the triple combination of PARPi, chemotherapy
and 177Lu-DAB4 on tumour growth and survival of LL2 tumour-bearing mice was tested.
Results: La was over-expressed at both mRNA and protein levels in surgical specimens of human lung cancer and
the over-expression of La mRNA conferred a poorer prognosis. DAB4 bound specifically to cisplatin-induced dead
LL2 cells in vitro. An anti-tumour dose response was observed when escalating doses of 177Lu-DAB4 were delivered
in vivo, with supra-additive responses observed when chemotherapy was combined with 177Lu-DAB4. Combining
PARPi with chemotherapy was more effective than chemotherapy alone with increased tumour cell DNA damage
and death, and intratumoural DAB4 binding. The combination of PARPi, chemotherapy and 177Lu-DAB4 was
well-tolerated and maximised tumour growth delay.
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Conclusions: The La antigen represents a dead cancer cell-specific target in lung cancer, and DAB4 specifically
targeted tumour tissue in vivo, particularly after chemotherapy. Tumour uptake of DAB4 increased further after the
combination of PARPi and chemotherapy, which generated new dead tumour cell-binding targets. Consequently,
combining 177Lu-DAB4 with PARPi and chemotherapy produced the greatest anti-tumour response. Therefore, the
triple combination of PARPi, chemotherapy and RIT may have broad clinical utility.
Keywords: APOMAB®; La/SSB antigen; Lewis lung carcinoma; PARP inhibitor; Lutetium-177; Bystander killingBackground
Lung cancer, particularly the common non-small cell lung
cancer (NSCLC) variant, is one of the major contributors
to cancer death worldwide [1]. Moreover, the global inci-
dence of NSCLC continues to rise, particularly among
females in developed economies, and generally among
persons in emerging economies. Metastatic NSCLC is
typically incurable, with standard first-line treatment for
good-performance status patients being platinum-based
doublet chemotherapy which is believed to have reached
an efficacy plateau. More recently, the identification of
molecular lesions in NSCLC, such as activating mutations
of the epidermal growth factor receptor (EGFR) gene and
fusions of the anaplastic lymphoma kinase (ALK) gene,
has yielded targets for small-molecule kinase inhibitors,
which often produce regressions and durable tumour con-
trol [2]. Nevertheless, the need for innovative improve-
ments to platinum-based chemotherapy remains because
kinase inhibitors do not cure, and other clinically action-
able molecular lesions are found in approximately half
of NSCLC cases [3]. Furthermore, post-operative cisplatin-
based chemotherapy is the standard treatment for
good-performance status patients with completely resected
early-stage NSCLC because chemotherapy confers a
5-year absolute survival benefit of 5.4% [4].
Targeting tumours with therapeutic monoclonal anti-
bodies (mAbs) has proven to be an effective approach to
cancer therapy although its clinical effectiveness has
been more limited in NSCLC with the vascular endothelial
growth factor-neutralising mAb, bevacizumab, the only
approved therapy. Hence, lung cancer is relatively bereft
of cell-surface targets for antibody therapies. The anti-
tumour potency of mAbs can be improved by arming
mAbs with radionuclides and cytotoxic drugs, creating the
new therapeutic modalities of radioimmunotherapy (RIT)
and antibody drug conjugates, respectively. Although
armed mAbs usually target tumour cell-surface antigens,
they can also elicit bystander killing of surrounding,
antigen-negative tumour cells [5,6]. Successful β-emitting
RIT has led to the approval of two agents for treating
CD20-positive B-cell lymphomas, although RIT for non-
haematological malignancies has been limited by heteroge-
neous antigen expression and radio-resistance among other
factors reviewed by [7].The lupus-associated (La) antigen, also known by the
HUGO Gene Nomenclature Committee approved name
of Sjögren Syndrome B (SSB), is an abundant, essential,
and ubiquitously expressed ribonucleoprotein that is
revealed preferentially in dead tumour cells because La
is over-expressed in malignancy [8-10] and dead tumour
cells are inefficiently cleared in vivo unlike dead normal
cells [10,11]. The La-specific mAb, DAB4 (APOMAB®),
targets dead tumour cells in vivo [12], particularly after
DNA-damaging anti-cancer treatment [10,11]. Using
DAB4 labeled with the β-emitter Yttrium-90 (90Y), we
have tested the concept of targeting dead tumour cells
as a way to deliver RIT to surrounding viable tumour
cells in murine syngraft and human xenograft models.
Compared to DAB4-directed RIT alone, prior treatment
with DNA-damaging cytotoxic chemotherapy resulted
in supra-additive anti-tumour responses, with the quality
of the responses ranging from significant tumour growth
delay in carcinoma models [11] to sustained complete re-
gression in a lymphoma model [13].
The safety and efficacy of RIT in carcinoma models may
be improved by altering the radionuclide used for RIT and
by combining RIT with radio-sensitising drugs or small mol-
ecule enzyme inhibitors [13]. Since carcinomas often evolve
because of defective DNA damage responses [14], DNA re-
pair inhibitors represent an attractive target for sensitising
resistant cancer cells to treatment [15]. One such target is
the family of Poly ADP ribose polymerases (PARP), three of
which (PARP-1, PARP-2, PARP-3) are involved in the DNA
damage response to DNA single strand breaks (SSB) [16].
Unrepaired SSB can result in collapsed replication forks and
formation of double-strand breaks (DSB) which are repaired
by homologous recombination (HR). Some tumour types
have defective HR repair and rely solely on SSB repair
through PARP signalling, and targeting PARP itself is suffi-
cient to cause synthetic lethality reviewed by [17]. PARPi are
also chemo- and radio-sensitising agents which reduce
DNA repair capacity, allowing accumulation of DNA dam-
age which can lead to cell death [18]. Additionally, some
PARP inhibitors have vasodilative properties [19], which
contribute to increased tumour sensitisation to radiation
[18,20] and some [21,22] but not [23] all chemotherapeutics.
In this study, we analysed expression of La mRNA in
normal and malignant lung tissues and the expression of
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We used 177Lu-DAB4 with or without radio-sensitising
chemotherapy for treating mice harbouring the well-
characterised chemo- and radio-resistant Lewis Lung
(LL2) tumour. We hypothesised that adding a PARPi to
the treatment regimen would sensitise tumour cells to
chemotherapy and generate more intratumoural dead
cell targets for DAB4 to bind. The increased tumour
accumulation of 177Lu-DAB4 together with continued
PARPi treatment would further sensitise tumour cells
to 177Lu-derived β-emissions, resulting in greater anti-
tumour activity.
Methods
Data-mining of La mRNA expression in lung cancer
The online cancer database Oncomine version 4.4.3
(Compendia Bioscience Inc., Ann Arbor, MI, USA) was
used to examine the mRNA expression of La in normal
versus cancerous lung tissue, with a p value significance
threshold set at <10−4.
Cell culture and antibody production
LL2 cells were cultured in RPMI-1640 (Sigma-Aldrich,
St. Louis, MO, USA) with 5% FCS (Bovogen Biologicals,
Keilor East, Victoria, Australia). DAB4 is a subclone of
the anti-La 3B9 hybridoma originated by Dr Michael
Bachmann [24] which was selected on the basis of higher
binding to a defined epitope of the La antigen. 3B9 was the
gift of Prof. Tom Gordon, SA Pathology, Flinders Medical
Centre, Adelaide, Australia. DAB4 and the isotype-specific
control mAb (Sal5) were produced and purified as previ-
ously described [10,25,26].
Detection of La protein in human tumour samples
A TissueFocus Cancer Survey Tissue Microarray (Origene,
Rockville, MD, USA) was dewaxed and endogenous perox-
idase activity was blocked with 0.5% hydrogen peroxide in
methanol. After washing in PBS, heat-induced antigen re-
trieval using citrate buffer (pH 6) was performed. The slide
was allowed to cool and washed twice with PBS followed
by blocking with 3% normal human serum. The slide
was incubated with 0.6 μg/mL DAB4 overnight at room
temperature, followed by biotinylated horse anti-mouse
IgG (Vector Laboratories, Burlingame, CA, USA) and stre-
pavidin conjugated horseradish peroxidase (Thermo-Fisher,
Waltham, MA, USA). To visualise antibody binding, the
microarray was incubated with 3′-diaminobenzide and
counterstained with Mayer’s Haematoxylin.
Antibody binding to LL2 cells
LL2 cells (105) were treated with varying concentrations
of cisplatin for 48 h, collected, washed with FACS buffer
(0.5% BSA, 0.04% sodium azide, PBS) and incubated with
10 μg/mL DAB4 or Sal5 for 15 min. Cells were washedand incubated with 2 μg/mL goat anti-mouse Alexa-488
(Life Technologies, Carlsbad, CA, USA) for 15 min, washed
further, incubated with 1 μg/mL DAPI (Sigma-Aldrich) and
analysed by flow cytometry (FACScanto flow cytometer, BD
Biosciences, Franklin Lakes, NJ, USA).
LL2 tumour model
All animal experiments were approved by the SA Pathology
Animal Ethics Committee, Adelaide, and conducted fol-
lowing institutional ethical guidelines. Six- to 8-week-old
female C57Bl/6 mice were injected subcutaneously in the
right flank with 106 LL2 cells. Tumour size was measured
using electronic calipers and tumour volume determined
using the calculation: tumour volume = (a2 × b)/2, where
a is the shortest diameter and b is the longest diameter
of the tumour. Treatment commenced when tumours
reached 30 to 50 mm3. Mice were monitored daily using a
clinical record sheet with points allocated for physical ob-
servations such as visible tumour, ruffled coat, hunched
posture, reluctance to move, diarrhoea, squealing when
handled and weight loss. Body weight and tumour volume
were measured every 2 days in the first week of treatment
and daily thereafter. Mice were humanely euthanized when
a clinical score of 5 was reached, weight loss was >15%
(cf. day 1), or tumour volume was >600 mm3.
Treatment of tumour-bearing mice
Tumour-bearing mice were treated intravenously with
50 mg/kg gemcitabine (Hospira, Melbourne, VIC, Australia)
on days 1 and 2 and 2.5 mg/kg cisplatin (Hospira) on day 1.
DAB4 and Sal5 were conjugated to the bi-functional
chelator DOTA-NHS (Macrocyclics, Dallas, TX, USA)
as previously described [11] and radiolabeled with 177Lu
(PerkinElmer, Waltham, MA, USA). Radioimmunocon-
jugates were administered intravenously on day 3. The
specific activity of radioimmunoconjugates ranged from
95 to 130 MBq/mg with >97% incorporation of 177Lu as
determined by instant thin layer chromatography. The
PARPi inhibitor Rucaparib (AG-014699; Selleck Chemicals,
Houston, TX, USA) was diluted in 5% D-glucose in PBS for
intraperitoneal injection at 1 or 2 mg/kg and administered
daily on days 1 to 5, 30 min before chemotherapy or RIT.
For in vivo antibody binding analysis, DAB4 was biotinyl-
ated with EZ-Link NHS-Biotin (Thermo Fisher) following
manufacturer’s instructions. One hundred micrograms of
biotin-DAB4 was administered 24 h after chemotherapy.
Tissue biodistribution studies
Mice were euthanized 24 h after RIT administration, tissues
were collected and weighed and radioactivity was measured
using a Wallac 2470 wizard2 gamma counter (PerkinElmer)
with peak detection set at 208 keV. Radioactivity in the
organs was normalized to the weight of the organ and
the accumulation was calculated as the percentage of
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injected dose of 177Lu-DOTA immunoconjugates (%ID/g).
High-resolution digital autoradiography was performed
on 4-μm tumour sections using a MicroImager (Biospace
Lab, Paris, France).
Ex vivo analysis of LL2 tumours
Mice were euthanized 24 h after administration of biotin-
DAB4, tumours were removed and snap frozen in OCT
cryoprotectant (Sakura Finetek, Torrance, CA, USA). Sec-
tions were fixed with 10% neutral-buffered formalin,
washed with PBS, blocked with 5% BSA with 0.3% Triton-
X 100 (Sigma-Aldrich), washed and incubated overnight
with rabbit anti-phospho-histone H2AX (Ser139) antibody
(1:300 dilution; Cell Signaling Techology, Danvers, MA,
USA). Sections were washed and incubated with donkey
anti-rabbit IgG NL557 (1:200 dilution; R and D systems,
Minneapolis, MN, USA). To detect biotin-DAB4, sec-
tions were concurrently incubated with strepavidin-
Alexa Fluor-488 (1:400; Life Technologies). Cell death
was detected using the ApopTag cell death detection kit
(Millipore, Billerica, MA, USA) following manufacturer’s
instructions. Sections were stained with 1 μg/mL DAPI,
and examined using an Olympus IX71 microscope with
CellSens Standard (v1.6) software and analysed using
ImageJ (v1.45) software (National Institute of Health,
Bethesda, MD, USA).
Statistical analysis
Measurements of association between La mRNA expression
and lung cancer outcomes [27] were performed using
WINPEPI software [28]. Tumour doubling times were
calculated as previously described [11]. Statistical analyses
were performed using GraphPad Prism (v5.0) software,
with data shown as mean ± SEM. Unless otherwise stated,
intergroup comparisons were made by analysis of vari-
ance (ANOVA, Bonferroni post-hoc test). Kaplan-Meier
median survival curves were compared using log-rank
(Mantel-Cox) test.
Results
La is over-expressed at the mRNA level in lung cancer
and exhibits strong immunostaining patterns in lung
cancer tissue
We used the Oncomine online gene expression database
to examine the expression of La mRNA in human lung
cancer samples compared to normal lung tissue. Two
studies [29,30] demonstrated a significant 1.5-fold and
1.3-fold increase in La mRNA expression in large cell
lung carcinoma (LCLC) and squamous cell lung carcinoma
(SCC), respectively (Figure 1A (part I)) and 1.2-fold in-
crease in lung adenocarcinoma (AC) compared to nor-
mal lung samples (Figure 1A (part II)). In a further
analysis, there was a higher death rate in patients inwhom surgical specimens of NSCLC had ≥2-fold in-
creased expression of La mRNA compared to those
whose tumours had <2-fold increased expression of La
mRNA (Table 1), with a rate ratio (95% CI) of 1.27
(1.07, 1.50; p = 0.008). This ratio was very similar when
adjusting for nodal status in a Mantel-Haenszel analysis
at 1.27 (1.08, 1.49), and heterogeneity testing showed
similarly elevated rate ratios for both the node-positive
and node-negative cases (p = 0.806).
The expression of La protein in lung cancer samples was
also investigated by immunohistochemistry using a cancer
tissue microarray stained with the La-specific mouse mAb,
DAB4 and scored by a pathologist. Only nuclear staining
with DAB4 was considered positive and scoring was based
on staining intensity (weak, moderate or strong) and
percentage of positively stained cells. In the 10 lung
cancer sections, all demonstrated strong staining; in
two sections, >95% tumour cells were positive, and in
the remaining eight sections, >99% tumour cells were
positive. In the 5 normal lung tissue sections, approxi-
mately 50% cell nuclei had weak to moderate DAB4
staining, mainly belonging to pneumocytes and endo-
thelial, inflammatory and stromal cells. As illustrated
in Figure 1B (parts I to IV), DAB4 stained nuclei of tumour
cells more intensely than the nuclei of some tumour
stromal cells. The most intense intranuclear staining of
DAB4 was found within the nucleoli, which featured
prominently in many malignant cells. In comparison,
only moderate nuclear staining of DAB4 was observed
among the epithelial and stromal cells of normal lung
tissues (Figure 1B (parts V and VI)).
DAB4 binding to dead LL2 cells in vitro
The murine lung cancer LL2 cell line was treated in vitro
with escalating doses of cisplatin for 48 h and binding of
DAB4 or its isotype control mAb (Sal5) to dead (DAPI+)
cells was examined. Cisplatin treatment resulted in a
dose-dependent increase in cell death (Figure 2). As the
percentage of dead cells increased, so did the proportion
of dead, DAB4-bound cells (Figure 2A), with >80% of
the dead cell population being bound by DAB4 after
treatment with 10 μg/mL cisplatin. Conversely, only
minimal binding of Sal5 (<3%) to dead cisplatin-treated
cells was observed (Figure 2B).
Treatment with 177Lu-DAB4 alone and in combination
with chemotherapy
Next, we investigated if 177Lu-DAB4 exhibited anti-tumour
activity that was similar to what we had previously
shown with 90Y-DAB4 [11] in the LL2 syngraft model.
As a monotherapy, 177Lu-DAB4 reduced tumour growth
and significantly increased median survival time (MST)
from 8 days for untreated mice to 10, 12 and 12 days after































































































Figure 1 Expression of La mRNA and protein in lung cancer. (A) The expression of La mRNA in normal compared to lung cancer samples
was examined using the online database Oncomine. Two studies showed increased La mRNA expression in lung cancer samples compared to
normal lung tissue. Data was taken from (I) Hou et al.’s study [30] and (II) Landi et al.’s study [29]. Data are shown with 95% confidence intervals
and circles representing outliers. LCLC, large cell lung cancer; SCC, squamous cell lung cancer; AC, adenocarcinoma. *** p < 0.001.
(B) Photomicrographs of DAB4 staining pattern in sections of resected human lung tumours. TissueFocus Cancer Survery Tissue Microarray
(Origene) was examined via immunohistochemistry for DAB4 expression. (I) Poorly differentiated squamous cell carcinoma of bronchus
(case No. 0000019032): tumour cells (T); hypocellular stroma (S) with variable DAB4 expression (evident as brown staining) of normal cells
including endothelial cells and other stromal cells (arrowheads). (II) Adenosquamous carcinoma (case No. 0000016518): predominantly basaloid
squamous cell carcinoma (T) with prominent DAB4-stained nucleoli (arrowheads); desmoplastic stromal reaction (S) with both DAB4-stained and
unstained nuclei of stromal cells (arrow). (III) Poorly differentiated adenocarcinoma (case No. 0000008378): acinar structures (A) are evidently
interweaved with a hypercellular stroma (S). Some malignant cells were not stained with DAB4 (arrowheads). (IV) Poorly differentiated lung
adenocarcinoma (case No. 0000016267): the high-grade malignant cells (T) are vacuolated and have weak non-specific cytoplasmic staining with
DAB4 (arrowheads); a desmoplastic stromal reaction (S) with DAB4-stained lymphoplasmacytic infiltrates (arrows). (V and VI) Normal lung tissue
(case No. 0000000144 and 0000006853) showed reduced, predominantly nuclear DAB4 staining. All sections are shown at × 20 magnification, and
scale bars are indicated.
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Table 1 Survival status of resected NSCLC patients
according to La mRNA expression levels
La expression
(compared to healthy tissue)
Survival status Number
per groupDead Alive
>2-fold increase 103 (61%) 65 (39%) 168
<2-fold increase 133 (48%) 142 (52%) 275
The mRNA expression of La and survival status of patients with resected
NSCLC was examined using Oncomine, with data originally derived from [27].
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promotes tumour accumulation compared to simultaneous
administration [12], 177Lu-DAB4 was given to LL2-tumour
bearing mice 24 h after completion of chemotherapy
(consisting of 50 mg/kg gemcitabine on days 1 and 2
and 2.5 mg/kg cisplatin on day 1; Figure 3B), which is
the peak time for chemotherapy-induced tumour cell
death [11]. The combination of chemotherapy and 5 or
7.5 MBq 177Lu-DAB4 further delayed tumour growth and
significantly increased MST to 19 and 21 days, respectively,
compared to chemotherapy alone (MST 12 days). The
combination of chemotherapy and 10 MBq 177Lu-DAB4
was not tolerated, and the entire cohort was euthanized
16 days after treatment because 60% of the treatment
group had a clinical score of 5. None of mice in the
remaining treatment groups had evident toxicity, with
only minimal and transient body weight loss observed
(Additional file 1: Figure S1) and a clinical score of no
more than 2. 177Lu-Sal5 alone or with chemotherapy was
not effective (Figure 3A,B). Tumour doubling times (TDT)
for treatment groups were determined and showed that
while 177Lu-DAB4 alone increased TDT linearly with dose,
the combination of chemotherapy and 177Lu-DAB4 re-
sulted in a supra-additive response (Figure 3C). A similar
supra-additive response was also observed when chemo-
therapy was combined with lower activities of 177Lu-DAB4,
a result which mirrored our previous findings with
90Y-DAB4 (Additional file 2: Figure S2).Figure 2 DAB4 binding to dead LL2 cells in vitro. LL2 cells were treated
dead cells was examined by flow cytometry. n = 3.Biodistribution of DAB4 in LL2 tumours
The tissue distribution of 177Lu-DAB4 and 177Lu-Sal5 in
LL2 tumour-bearing mice was examined to confirm whether
the therapeutic response of 177Lu-DAB4 was associated with
tumour-selective uptake of the radioimmunoconjugate.
When delivered alone, 177Lu-DAB4 tumour accumulation
was 1.6-fold higher than 177Lu-Sal5, with chemotherapy
further increasing 177Lu-DAB4 tumour accumulation
2.5-fold compared to mice treated with chemotherapy and
177Lu-Sal5 (Figure 4A). Chemotherapy did not significantly
affect the biodistribution of 177Lu-DAB4 in normal tissues,
indicating that 177Lu-DAB4 specifically targeted tumour
tissue after chemotherapy. β-microimaging of tumour
sections showed heterogeneous uptake of 177Lu-DAB4
which was increased after chemotherapy (Figure 4B).
PARPi increases the anti-tumour activity of chemotherapy
in vivo
As PARPi is a chemo-sensitising agent, we examined
whether the combination of PARPi and chemotherapy
could further reduce LL2 tumour growth in vivo. PARPi
treatment alone had minimal effect on tumour growth
and survival, whereas chemotherapy alone delayed tumour
growth and increased MST to 14 days which, when com-
bined with 1 or 2 mg/kg PARPi, further delayed tumour
growth and increased MST to 17 and 18 days, respectively
(Figure 5A,B). No treatment toxicity was evident, with the
PARPi-chemotherapy combination resulting in only slight
and reversible body weight loss (Additional file 3: Figure S3).
To determine whether DNA damage, cell death and
intratumoural DAB4 binding were altered within LL2
tumours after combination treatment, mice were ad-
ministered with PARPi and chemotherapy followed 24 h
later with biotin-DAB4. Mice were euthanized 24 h later
and tumours were analysed for DNA damage, cell
death and DAB4 binding. DNA damage evident as DSB
marked by γ-H2AX foci increased after chemotherapy,with cisplatin for 48 h and (A) DAB4 binding or (B) Sal5 binding to
Figure 3 Anti-tumour response of RIT alone or in combination with chemotherapy. LL2 tumour bearing mice were left untreated, or
treated with chemotherapy (chemo) and/or RIT (177Lu-DAB4 or 177Lu-Sal5). (A) Left panel, percentage change in tumour volume after treatment.
Right panel, Kaplan-Meier survival analysis, ** p < 0.01 compared to untreated mice, n = 5. (B) Comparison of the anti-tumour effect of escalating
doses of RIT when delivered after chemotherapy. Left panel, percentage change in tumour volume after treatment. Red symbols = toxic dose.
Right panel, Kaplan-Meier survival analysis, ** p < 0.01 compared to mice given chemotherapy alone, n = 5. (C) Mean tumour doubling times
derived from tumour growth curves are displayed as a function of RIT dose. Standard errors for data points range from 0.03 to 0.15, and are too
small to be evident as error bars. Data shows that the combination of chemotherapy and RIT is supra-additive because the slopes of the two lines
are significantly different (p = 0.02; analysis of covariance).
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chemotherapy (Figure 5C). Chemotherapy also signifi-
cantly increased tumour cell death, with the combination
of PARPi and chemotherapy resulting in the greatest
amount of cell death (Figure 5D). Tumour DAB4 bind-
ing was commensurate with treatment-induced cell
death (Figure 5E), due in part to DAB4 binding to dead
tumour cells (Figure 5F).
Triple combination of PARPi, chemotherapy and 177Lu-DAB4
We next examined whether administering 177Lu-DAB4
in combination with PARPi and chemotherapy couldfurther potentiate the anti-tumour response. The com-
bination of PARPi with chemotherapy, 177Lu-DAB4 or
the triple combination of PARPi, chemotherapy and
177Lu-DAB4 were well tolerated with only transient and re-
versible weight loss observed after the triple combination
(Figure 6A), with no evident physical signs of distress or
discomfort. Combining PARPi with 5 MBq 177Lu-DAB4 or
chemotherapy increased tumour growth delay (Figure 6B)
and significantly improved survival of mice (MST of 15 and
18 days for mice treated with PARPi and RIT or chemo-
therapy, respectively) compared to the equivalent treatment
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Figure 4 Biodistribution of 177Lu-DAB4 in LL2 tumour-bearing mice. LL2 tumour-bearing mice were given RIT (177Lu-DAB4 or 177Lu-Sal5)
alone or after chemotherapy (chemo), and (A) Tissue accumulation of radioactivity was assayed. * p < 0.05 (two-way ANOVA), n = 4. (B) The same
tumours were sectioned, and imaged using a MicroImager.
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The triple combination of chemotherapy, PARPi and
177Lu-DAB4 produced the greatest anti-tumour response,
with a significant increase in survival (MST of 25 days)
compared to mice which received only chemotherapy
and 5 MBq 177Lu-DAB4 (MST of 21 days). Analysis of
the TDT for each treatment group demonstrated that
the addition of PARPi to the treatment regimens of
RIT, chemotherapy or combination of chemotherapy
and RIT resulted in an increase in TDT greater than
would be expected if the addition of PARPi was only
additive (Additional file 4: Figure S4).Discussion
The La antigen represents a suitable target for RIT as it is
highly abundant and over-expressed at both the mRNA
and protein level in malignant human cell cultures [10,31]
and in primary human cancers [8,9,31]. Moreover, over-
expression of La mRNA portends a worse prognosis in
surgically resected NSCLC [27]. La is normally located
within the nucleus where it protects nascent RNA from
exonucleases reviewed by [32], making it inaccessible to
antibody binding. During cell death, La is redistributed
to the cytoplasm through protease-mediated cleavage
of its C-terminal nuclear localisation signal [33]. This,
Figure 5 Combination of PARPi with chemotherapy increases tumour growth delay, DNA damage, tumour cell death, and tumour
uptake of DAB4 in vivo. LL2 tumour-bearing mice were administered PARPi alone or with chemotherapy (chemo). (A) Percentage change in
tumour volume after treatment (B) Kaplan-Meier survival analysis. * p < 0.05 compared to untreated or chemotherapy alone, n = 4 to 5. Tumour
sections were examined for (C) γ-H2AX, (D) cell death (ApopTag+) and (E) DAB4 binding. * p < 0.05, ** p < 0.01, *** p <0.001, n = 3. (F) Shows
(i) DAPI-counterstained tumour section with detection of (ii) cell death (ApopTag+), and (iii) biotinylated DAB4 with merged images shown in
(iv; yellow = co-localisation of DAB4 with dead cells). Bar = 50 μm.
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death, make La accessible to DAB4 binding and means
that DAB4 preferentially binds to dead tumour cells[10]. This was evident as DAB4 only bound to treatment-
induced dead LL2 cells and did not bind to viable
LL2 cells.
Figure 6 PARP inhibition potentiates the anti-tumour effects of individual and combination treatments with chemotherapy and RIT.
LL2 tumour-bearing mice were treated with PARPi on days 1 to 5, chemotherapy on days 1 and 2 and 5 MBq 177Lu-DAB4 on day 3. (A) Weight
changes of mice after treatment. (B) Percentage change in tumour volume after treatment. (C) Kaplan-Meier survival analysis. ** p < 0.01 com-
pared to same treatment group but without PARPi administration.
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tumour activity, with the response to 7.5 and 10 MBq
doses of 177Lu-DAB4 being comparable to chemotherapy.
The similar tumour responses to 7.5 and 10 MBq doses
(corresponding to approximately 75 and 100 μg of mAb
per mouse, respectively) suggest that a saturating dose for
177Lu-DAB4 monotherapy had been reached, perhaps
because of a limiting number of DAB4-binding dead
tumour cell targets [25]. The combination of chemotherapy
with 177Lu-DAB4 resulted in a supra-additive anti-tumour
response, and reflected the similar supra-additive response
observed with combined chemotherapy and 90Y-DAB4,
which we characterised as a ‘genotoxic chain reaction’
[11]. Moreover, 90Y-DAB4 and 177Lu-DAB4 behaved asresidualizing radioimmunoconjugates after combination
chemotherapy and RIT (chemo-RIT): intratumoural,
detergent-resistant 90Y-DAB4 was found 96 h post-
chemo-RIT [11], and 177Lu-DAB4 was found in LL2 tu-
mours 24 h post-chemo-RIT. The complex mechanism
involved in the supra-additive responses may depend on
at least two factors:
(i) increased chemotherapy-induced tumour cell death
with the associated increase in intratumoural binding
of 177Lu-DAB4 results in radiation crossfire as
177Lu-generated β-particles can kill cells up to 50 cell
diameters from antibody-bound target cells [34], thus
generating ever more dead cell targets;
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additional targets for circulating 177Lu-DAB4 to bind
thereby permitting continued irradiation of
surrounding viable tumour cells.
Furthermore, the MTD of 177Lu-DAB4 alone or with
chemotherapy was higher than that observed for 90Y-DAB4
(MTD of 5 MBq) in the LL2 tumour model [11]. As both
177Lu and 90Y are used for clinical RIT, we suggest that
177Lu may have combined safety and efficacy advantages
over 90Y as a therapeutic β-emitter, at least in treating small
tumour volumes [35]. β-particles derived from the decay of
177Lu vs 90Y have a lower maximum energy (0.5 MeV with
79% occurrence vs 2.2 MeV with 99% occurrence), lower
dose-rate constant (0.076 and 0.54 Gy.g/MBq.h), shorter
range (maximum tissue penetration 2 mm vs 11 mm), but
a longer half-life (6.71 days vs 2.67 days). Therefore, the
likelihood that the radiation dose absorbed by suscep-
tible tissues such as gut and bone marrow will be lower
and that more radiation dose will be absorbed for longer
within the confines of the shrinking tumour favours
177Lu-DAB4 rather than 90Y-DAB4 for La-targeted RIT
post-chemotherapy. Consequently, we introduce the
concept of ‘volume-adapted radioimmunotherapy’ to
describe the match between the physical characteristics of
177Lu and tumour size post-chemotherapy treatment.
As the combination of PARPi with chemotherapy or
radiotherapy has been shown to have greater potency
than each individual treatment [18], we reasoned that
the combination of PARPi with chemotherapy should
exhibit greater anti-tumour activity than chemotherapy
alone. Indeed, combining PARPi with chemotherapy
showed greater anti-tumour activity than chemother-
apy alone which was due, in part, to an increase in
DNA damage and cell death within the tumour. PARPi
also potentiated the anti-tumour response to RIT. Although
outside the scope of this study, PARPi have been reported
to increase autophagy and reduce proliferation within
tumours especially when combined with radiation [18],
and these mechanisms could also be involved in the anti-
tumour responses observed here. However, the greatest
anti-tumour response was observed with the triple combin-
ation of PARPi, chemotherapy and RIT. This unique com-
bination approach depends entirely on β-radiation crossfire
for its therapeutic effectiveness as DAB4 alone has no anti-
tumour activity [11]. Therefore, we argue that the addition
of a PARP inhibitor to chemo-RIT creates more necrotic
tumour cell targets for DAB4 binding and further increases
tumour shrinkage, which together enhance the potency of
La-directed and volume-adapted RIT.
Nevertheless, tumours were not eradicated after a single
cycle of triple combination therapy. Among the possible ex-
planations is that the LL2 cell line is known to have mutant
p53 [36], and altered p53 expression reduces sensitivity toPARPi [37]. Hence, other radio-sensitising agents such as
anti-EGFR mAb may be used to augment chemo-RIT.
For example, a neutralising mouse anti-EGFR mAb,
which alone displays anti-tumour activity in the Lewis
Lung carcinoma model [38], could be added to the treat-
ment regimen to radio-sensitise tumour cells as well as
directly inhibit tumour growth. Supporting evidence for
this approach is found in the only other known study of
the triple combination of PARPi, chemotherapy and RIT
(using 177Lu-labeled anti-human EGFR mAb). Here,
complete eradication of pulmonary metastases and
patient-derived xenografts of human triple-negative breast
cancer was achieved in immunodeficient mice. This effect
of triple therapy was attributed to an increase in tumour
cell death and killing of putative breast cancer stem cells
[39], which may have been aided by EGFR-mediated inhib-
ition of DNA DSB repair, particularly in PARPi-sensitised
breast cancer cells.Conclusion
In conclusion, using RIT with 177Lu as the payload, we
have shown that La-targeted RIT is well tolerated and able
to inhibit growth of LL2 tumour syngrafts pre-treated with
chemotherapy. Moreover, the addition of a PARPi potenti-
ated the anti-tumour effects of both chemotherapy and
RIT. Additional approaches such as repeated cycles of RIT,
conjugation to α-emitting radionuclides, or chemo-RIT
combinations with inhibitors of EGFR signalling, cell cycle
checkpoints, or DNA repair, may contribute to eradication
of LL2 tumours. Nonetheless, here we demonstrate the
principle that bystander killing by a short-range β-emitter is
a feasible and active approach to the treatment of lung
cancer. This approach may find clinical application as
consolidation treatment for such standard treatments
as platinum-based chemotherapy and radiotherapy in
advanced disease and adjuvant settings.Additional files
Additional file 1: Figure S1. Mouse body weight change after
treatment with RIT alone or in combination with chemotherapy. Figure
S1 Mice were treated with RIT alone or with chemotherapy (chemo) as
described in Methods. The percent change in mouse weights for mice
treated with RIT alone (A) or chemotherapy and RIT (B) are shown, n = 5.
Additional file 2: Figure S2. LL2 tumour doubling time after treatment
with 177Lu-DAB4 or 90Y-DAB4 alone or in combination with chemotherapy.
Figure S2 Mean tumour doubling times (TDT) for tumour-bearing mice
treated with (A) 177Lu-DAB4 or (B) 90Y-DAB4 alone or combined with
chemotherapy were derived from tumour growth curves. The broken line
represents the TDT if the combination of chemotherapy and RIT were
additive. Data from (B) has been published previously in [11].
Additional file 3: Figure S3. Mouse body weight changes after
treatment. Figure S3 Mice were treated with PARPi inhibitor (1 or 2 mg/kg)
alone or with chemotherapy (chemo) as described in Methods. The percent
change in mouse weights for mice treated with PARPi alone (A) or PARPi
and chemotherapy (B) are shown, n = 4–5.
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http://www.ejnmmires.com/content/4/1/2Additional file 4: Figure S4. LL2 tumour doubling time after treatment
regimens including PARPi, chemotherapy or RIT. Figure S4 Mean tumour
doubling times (TDT) for tumour-bearing mice in each treatment group were
derived from tumour growth curves. Filled bars indicate increases in TDT that
would be expected from adding the effects of component treatments,
whereas open bars indicate the observed TDT for treatments. Additive effects
were calculated by deducting the TDT of the untreated group from the TDT
of the PARPi treatment group and adding that to the TDT of the group of
interest, e.g. TDTPARPi + RIT = TDTRIT + (TDTPARPi – TDTuntreated).
Competing interests
MP Brown, F Al-Ejeh and JM Darby are co-inventors on APOMAB-related
patents both issued and pending.
Authors’ contributions
AHS designed and performed experiments, collected the data, performed
statistical analysis and wrote the paper. FA designed and performed
experiments, collected the data and performed statistical analysis. CKF and
JMD were involved with in vivo experiments and data collection. DMR
performed data analysis comparing survival of NSCLC patients with La
expression and performed statistical analysis. AR analysed the Tissue
microarray and JM developed and performed immunohistochemistry and
imaging of the Tissue microarray. MPB participated in the design of the
study, data collection, analysis and interpretation, and in writing the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank Dr. Carleen Cullinane and Prof. Rod Hicks (Peter MacCallum Cancer
Centre, Melbourne) for performing autoradiography, Dr David Moffat
(Department of Tissue Pathology, SA Pathology, Adelaide) for helpful
interpretations of tissue microarray data, and the staff at the SA Pathology
Animal Care Facility for their assistance. This work was supported in part by
the National Health and Medical Research Council (Project Grant ID511303).
Author details
1Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology,
Adelaide, Australia. 2School of Pharmacy and Medical Science, University of
South Australia, Adelaide, Australia. 3Signal Transduction Laboratory,
Queensland Institute of Medical Research, Brisbane, Australia. 4Cancer
Epidemiology and Population Health, School of Population Health, University
of South Australia, Adelaide, Australia. 5Gastroenterology Research
Laboratory, Centre for Cancer Biology, SA Pathology, Adelaide, Australia.
6Centre for Neurological Diseases, SA Pathology, Adelaide, Australia. 7Cancer
Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, Australia. 8School of
Medicine, University of Adelaide, Adelaide, Australia. 9Current affiliation:
Preclinical Imaging and Research Laboratories, South Australian Health and
Medical Research Institute, Adelaide, Australia. 10Experimental Therapeutics
Laboratory, Level 4 Hanson Institute Building North, Royal Adelaide Hospital,
North Terrace, Adelaide, SA 5000, Australia.
Received: 24 September 2013 Accepted: 23 December 2013
Published: 4 January 2014
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
2. Li T, Kung HJ, Mack PC, Gandara DR: Genotyping and genomic profiling of
non-small-cell lung cancer: implications for current and future therapies.
J Clin Oncol 2013, 31:1039–1049.
3. Oxnard GR, Binder A, Janne PA: New targetable oncogenes in non-small-cell
lung cancer. J Clin Oncol 2013, 31:1097–1104.
4. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ,
Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R,
Aubert D, Ding K, Waller D, Le Chevalier T, LACE Collaborative Group:
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE
Collaborative Group. J Clin Oncol 2008, 26:3552–3559.
5. Enger SA, Hartman T, Carlsson J, Lundqvist H: Cross-fire doses from
beta-emitting radionuclides in targeted radiotherapy. A theoretical study
based on experimentally measured tumor characteristics. Phys Med Biol
2008, 53:1909–1920.6. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA,
Chittenden T, Blättler WA, Goldmacher VS: Antibody-drug conjugates
designed to eradicate tumors with homogeneous and heterogeneous
expression of the target antigen. Cancer Res 2006, 66:3214–3221.
7. Song H, Sgouros G: Radioimmunotherapy of solid tumors: searching for
the right target. Curr Drug Deliv 2011, 8:26–44.
8. Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, Guerzoni C, Santilli G,
Byrom MW, Goldoni S, Ford LP, Caligiuri MA, Maraia RJ, Perrotti D,
Calabretta B: BCR/ABL activates mdm2 mRNA translation via the La
antigen. Cancer Cell 2003, 3:145–160.
9. Sommer G, Rossa C, Chi AC, Neville BW, Heise T: Implication of RNA-
binding protein La in proliferation, migration and invasion of lymph
node-metastasized hypopharyngeal SCC cells. PLoS ONE 2011, 6:e25402.
10. Al-Ejeh F, Darby JM, Brown MP: The La autoantigen is a malignancy-associated
cell death target that is induced by DNA-damaging drugs. Clin Cancer Res
2007, 13:5509s–5518s.
11. Al-Ejeh F, Darby JM, Brown MP: Chemotherapy synergizes with
radioimmunotherapy targeting la autoantigen in tumors. PLoS ONE
2009, 4:e4630.
12. Al-Ejeh F, Darby JM, Tsopelas C, Smyth D, Manavis J, Brown MP: APOMAB,
a La-specific monoclonal antibody, detects the apoptotic tumor response to
life-prolonging and DNA-damaging chemotherapy. PLoS ONE 2009, 4:e4558.
13. Al-Ejeh F, Brown MP: Combined Modality Therapy: Relevance for
Targeted Radionuclide Therapy. In Targeted Radionuclide Therapy. 1st
edition. Edited by Speer TW. Philadelphia: Lippincott, Williams & Wilkinson;
2011:220–235.
14. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M,
Nesland J, Lukas C, Ørntoft T, Lukas J, Bartek J: DNA damage response as a
candidate anti-cancer barrier in early human tumorigenesis. Nature 2005,
434:864–870.
15. Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK:
Harnessing the complexity of DNA-damage response pathways to
improve cancer treatment outcomes. Oncogene 2010, 29:6085–6098.
16. Sousa FG, Matuo R, Soares DG, Escargueil AE, Henriques JA, Larsen AK, Safi J:
PARPs and the DNA damage response. Carcinogenesis 2012, 33:1433–1440.
17. Javle M, Curtin NJ: The role of PARP in DNA repair and its therapeutic
exploitation. Br J Cancer 2011, 105:1114–1122.
18. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A,
Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B: Inhibition of poly
(ADP-ribose) polymerase enhances cell death and improves tumor growth
delay in irradiated lung cancer models. Clin Cancer Res 2007, 13:3033–3042.
19. Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S,
Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ: Vasoactivity of AG014699,
a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase:
a contributory factor to chemopotentiation in vivo? Clin Cancer Res 2009,
15:6106–6112.
20. Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ,
Wedge SR, Stratford IJ: Inhibition of PARP-1 by olaparib (AZD2281)
increases the radiosensitivity of a lung tumor xenograft. Mol Cancer
Ther 2011, 10:1949–1958.
21. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S,
Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR,
Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE,
Williams KJ, Curtin NJ: Anticancer chemosensitization and radiosensitization
by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer
Inst 2004, 96:56–67.
22. Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, Kyle S, Skalitzky D,
Li J, Zhang C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR,
Curtin NJ: Identification of potent nontoxic poly(ADP-Ribose) polymerase-1
inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res
2003, 9:2711–2718.
23. Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ,
Williams KJ: The clinically active PARP inhibitor AG014699 ameliorates
cardiotoxicity but does not enhance the efficacy of doxorubicin, despite
improving tumor perfusion and radiation response in mice. Mol Cancer Ther
2011, 10:2320–2329.
24. Kremerskothen J, Nettermann M, op de Bekke A, Bachmann M, Brosius J:
Identification of human autoantigen La/SS-B as BC1/BC200 RNA-binding
protein. DNA Cell Biol 1998, 17:751–759.
25. Al-Ejeh F, Darby JM, Pensa K, Diener KR, Hayball JD, Brown MP: In vivo
targeting of dead tumor cells in a murine tumor model using a
Staudacher et al. EJNMMI Research 2014, 4:2 Page 13 of 13
http://www.ejnmmires.com/content/4/1/2monoclonal antibody specific for the La autoantigen. Clin Cancer Res
2007, 13:5519s–5527s.
26. Al-Ejeh F, Darby JM, Thierry B, Brown MP: A simplified suite of methods to
evaluate chelator conjugation of antibodies: effects on hydrodynamic
radius and biodistribution. Nucl Med Biol 2009, 36:395–402.
27. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL,
Eschrich S, Jurisica I, Giordano T, Misek D, Chang A, Zhu C, Strumpf D,
Hanash S, Shepherd F, Ding K, Seymour L, Naoki K, Pennell N, Weir B,
Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M,
Rusch V, Kris M, Viale A, et al: Gene expression-based survival
prediction in lung adenocarcinoma: a multi-site, blinded validation study.
Nat Med 2008, 14:822–827.
28. Abramson JH: WINPEPI (PEPI-for-Windows): computer programs for
epidemiologists. Epidemiol Perspect Innovat 2004, 1:6.
29. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann E,
Fukuoka J, Hames M, Bergen A, Murphy S, Yang P, Pesatori A, Consonni D,
Bertazzi PA, Wacholder S, Shih J, Caporaso N, Je J: Gene expression
signature of cigarette smoking and its role in lung adenocarcinoma
development and survival. PLoS ONE 2008, 3:e1651.
30. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P,
van der Leest C, van der Spek P, Foekens J, Hoogsteden H, Philipsen S:
Gene expression-based classification of non-small cell lung carcinomas
and survival prediction. PLoS ONE 2010, 5:e10312.
31. Sommer G, Dittmann J, Kuehnert J, Reumann K, Schwartz PE, Will H, Coulter BL,
Smith MT, Heise T: The RNA-binding protein La contributes to cell
proliferation and CCND1 expression. Oncogene 2011, 30:434–444.
32. Wolin SL, Cedervall T: The La protein. Annu Rev Biochem 2002, 71:375–403.
33. Ayukawa K, Taniguchi S, Masumoto J, Hashimoto S, Sarvotham H, Hara A,
Aoyama T, Sagara J: La autoantigen is cleaved in the COOH terminus and
loses the nuclear localization signal during apoptosis. J Biol Chem 2000,
275:34465–34470.
34. Schlom J, Siler K, Milenic DE, Eggensperger D, Colcher D, Miller LS,
Houchens D, Cheng R, Kaplan D, Goeckeler W: Monoclonal antibody-based
therapy of a human tumor xenograft with a 177lutetium-labeled
immunoconjugate. Cancer Res 1991, 51:2889–2896.
35. Scott AM: Radioimmunotherapy of prostate cancer: does tumor size
matter? J Clin Oncol 2005, 23:4567–4569.
36. Rizzo MG, Soddu S, Tibursi G, Calabretta B, Sacchi A: Wild-type p53
differentially affects tumorigenic and metastatic potential of murine
metastatic cell variants. Clin Exp Metastasis 1993, 11:368–376.
37. Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL: Differential
anti-proliferative activities of poly(ADP-ribose) polymerase (PARP)
inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat
2012, 134:649–659.
38. Garrido G, Rabasa A, Sanchez B, Lopez MV, Blanco R, Lopez A, Hernández DR,
Pérez R, Fernández LE: Induction of immunogenic apoptosis by blockade of
epidermal growth factor receptor activation with a specific antibody.
J Immunol 2011, 187:4954–4966.
39. Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP,
Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK:
Treatment of Triple-Negative Breast Cancer Using Anti-EGFR Directed
Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and
PARP Inhibitor. J Nucl Med 2013, 54:913–921.
doi:10.1186/2191-219X-4-2
Cite this article as: Staudacher et al.: The La antigen is over-expressed in
lung cancer and is a selective dead cancer cell target for radioimmu-
notherapy using the La-specific antibody APOMAB®. EJNMMI Research
2014 4:2. Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
